Abstract: A microstructured or nanostructured multi-component ceramic comprises (a) a major ceramic phase comprising a ceramic oxide composite; (b) a ceramic oxide additive; and (c) a rare earth ceramic oxide additive, wherein the total of the additives (b) and (c) comprise from about 0.1 weight percent to less than 50 weight percent based on the total weight the multi-component ceramic composite. In another embodiment, a microstructured or nanostructured multi-component ceramic comprises (a) a major ceramic oxide phase comprising a ceramic oxide composite; and either (b) a ceramic oxide additive or (c) a rare earth ceramic oxide additive, wherein amount of the additive (b) or (c) comprises from about 0.1 weight percent to less than 50 weight percent based on the total weight the multi-component ceramic composite. Such ceramics are useful as bulk materials or as feedstocks for thermal spray.

Abstract: A catalyst composition for the polymerization of olefins is provided which comprises a catalyst compound and a co-catalyst or a support material or both a co-catalyst and a support material, wherein the catalyst compound comprises a transition metal of Group 4, 5 or 6, an organic compound containing at least one lone pair of electrons, a divalent radical and a Lewis basic group having the following formula: —C(R7)=Z1R8,  (i) wherein R7 and R8 are each independently selected from the group consisting of hydrogen and C1-C8 hydrocarbyl groups, and wherein R7 and R8 are not linked or are linked to form a saturated or unsaturated ring; and Z1 is a nitrogen atom or a phosphorus atom, which bonds to M; or  wherein: Z2 is an oxygen atom, a sulphur atom or a selenium atom, which bonds to the transition metal compound; and R9, R10 and R11 are each independently selected from the group consisting of hydrogen and C1-C8 hydrocarbyl groups, wherein no pair or one pair of su

Abstract: The present invention relates to organometallic compounds of transition metals with an indenyl ligand bonded in the 2-position and substituted in the 1,3-position, a process for their production, and their use as catalysts for the (co)polymerization of olefinic and/or diolefinic monomers.

Abstract: By controlling the hold up times, concentrations and temperatures for mixing the components of aluminum, titanium and magnesium based catalyst for solution polymerization it is possible to prepare a catalyst having a high activity, which prepares high molecular weight polyolefins. Generally, a catalyst loses activity and produces lower molecular weight polymer at higher temperatures. The catalyst of the present invention permits comparable polymers to be produced with higher catalyst activity and at higher reaction temperatures by increasing the concentration of the components used during the preparation of the catalyst.

Abstract: An improved noble metal alloy composition for a fuel cell catalyst, the alloy containing platinum, ruthenium, and nickel. The alloy shows methanol oxidation activity.

Abstract: A substrate includes a non-conductive portion to be electroless-plated of a substrate, on the surface of which fine metal catalyst particles composed of silver nuclei and palladium nuclei each having an average particle size of 1 nm or less adhere at a high nuclei density of 2000 nuclei/&mgr;m2 or more. The metal catalyst particles are produced by sensitizing the non-conductive portion of the substrate by dipping the substrate in a sensitizing solution containing bivalent tin ions, activating the non-conductive portion of the substrate by dipping the substrate in a first activator containing silver ions, and activating the non-conductive portion of the substrate by dipping the substrate in a second activator containing palladium ions.

Abstract: The present invention relates to a regulation composition for gametophytic self-incompatibility which contains sulfates especially CuSO4 and ZnSO4 as an inhibitor, which prevents a style-specific RNase activity regulating gametophytic self-incompatibility; a control method for gametophytic self-incompatibility of a plant by using the regulation composition for gametophytic self-incompatibility; and a plant self-pollinated by destroying the gametophytic self-incompatibility, using the control method. By using the regulation composition for gametophytic self-incompatibility according to the present invention, a single species of fruit trees can be self-pollinated without cultivating other pollinizer, so that fruition rate can be increased and the productivity per unit area can be maximized.

Abstract: Herbicide combinations (A)+(B), if appropriate in the presence of safeners, with an effective content of (A) broad-spectrum herbicides from the group (A1) glufosinate (salts) and related compounds (A2) glyphosate (salts) and related compounds such as sulfosate, (A3) imidazolinones such as imazethapyr, imazapyr, imazaquin, imazamox or their salts and (A4) herbicidal azoles from the group of the protoporphyrinogen oxidase inhibitors (PPO inhibitors) and (B) one or more herbicides from the group of the compounds consisting of (B0) one or more structurally different herbicides from the abovementioned group (A) and/or (B1) foliar- and/or soil-acting herbicides which are particularly effective selectively in cereals against monocotyledonous harmful plants and/or (B2) predominantly foliar-acting herbicides which are effective selectively in cereals against monocotyledonous and dicotyledonous harmful plants and/or (B3) foliar- and soil-acting herbicides which are effective selectively in cereals agains

Abstract: Water dispersible granules comprising (a) N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide, (b-1) an arylsulfonic acid formalin condensate or its salt, (b-2) a polycarboxylate surfactant and (c) a mineral carrier have a good disintegrability in water and can be produced in good yield.

Abstract: The present invention relates to biodegradable chemical compositions wherein core substrates, particularly oil well chemicals, are adsorbed onto particulate starch, particularly granular starch, providing a stable, controlled release formulation suitable for use in oil field applications. The invention further relates to the process of preparing obtaining these compositions.

Abstract: There is provided a grease composition useful for bearings of cars and aircraft which is stable in a wide range of temperature of 40 to 180° C. and exhibits low torque properties under high loading at low temperatures. A low torque grease composition having dynamic viscosity (40° C.) of 40 to 150 mm2/sec which comprises a base oil consisting of (a) straight-chain perfluoropolyether oil having dynamic viscosity (40° C.) of 25 mm2/sec or less and represented by the following general formula: RfO(CF2O)p(C2F4O)q(C3F6O)rRf, wherein Rf is a perfluoro lower alkyl group and all of p, q and r is an integer and a sum thereof is an integer of 25 to 45 and (b) straight-chain perfluoropolyether oil having dynamic viscosity (40° C.) of 250 mm2/sec or more and represented by the following general formula: RfO(CF2O)p(C2F4O)q(C3F6O)rRf, wherein Rf is a perfluoro lower alkyl group and p, q and r are an integer of 10 to 20; and (c) polytetrafluoroethylene as a thickener.

Abstract: A lubricating oil composition comprising a) an oil of lubricating viscosity having a viscosity index of at least 95; b) at least one calcium detergent; c) at least one oil soluble molybdenum compound; d) at least one organic ashless nitrogen-free friction modifier; and e) at least one metal dihydrocarbyldithiophosphate compound, the composition having a Noack volatility of about 15 wt. % or less, from 0.05 to 0.6 wt. % calcium from the calcium detergent, molybdenum in an amount of at least 10 ppm from the molybdenum compound, and phosphorus from the metal dihydrocarbyldithiophosphate compound in an amount up to about 0.1 wt. %.

Abstract: The invention relates to compositions for cables filling wherein a styrene-butadiene block copolymer with radial structure is used as a gelling agent. This polymer is obtained through styrene and butadiene sequential polymerization and subsequent reaction with a coupling agent preferably of type Cl4-nMRn, wherein M=Sn or Si, R is an alkyl or aryl group and n is an integer from 0 to 2, and hydrogenation of the resulting polymer. This type of copolymer brings a higher stability to the final properties of the gel as compared with the linear hydrogenated synthetic rubbers usually used in the prior art.

Abstract: Automatic dishwashing detergent compositions comprising diacyl peroxide bleaching agent and blooming perfume composition containing blooming perfume ingredients having a boiling point of less than about 260° C. and a ClogP of at least about 3, and delayed blooming perfume ingredients having a boiling point of less than about 260° and a ClogP of less than about 3, wherein the weight ratio of blooming perfume ingredients to delayed blooming perfume ingredients is from about 0.25 to about 1.5.

Abstract: Compositions for cleansing are disclosed that are not irritating to human skin. A composition is disclosed that includes at least 2% of a mixture of a salt of an alkyl sulfoacetate and a salt of an ethoxylated alkyl sulfosuccinate, at least 3% of a salt of an ethoxylated alkyl sulfate, at least 1% of an amphoteric surfactant, at least 0.05% of an alkyl glucoside, and at least 0.005% of a phospholipid. A composition for cleansing is disclosed that includes about 2% to 70% of a mixture of a salt of an alkyl sulfoacetate and a salt of an ethoxylated alkyl sulfosuccinate, about 3% to 40% of a salt of an ethoxylated alkyl sulfate, about 1% to 40% of an amphoteric surfactant, about 0.05% to 10% of an alkyl glucoside, and about 0.005% to 10% of a phospholipid.

Abstract: An antimicrobial composition comprising an alcohol in an amount from about 60 to about 95 weight percent of the total composition, a preservative, a cationic cellulose polymer thickening agent, a moisturizer and/or, a cationic emulsifier, and water in an amount from about 6 to about 30 weight percent. The skin disinfecting formulation will not irritate, dry or crack the skin and will provide antimicrobial effectiveness to the skin.

Abstract: The present invention relates to a process for making a multiphase personal wash bar having artisan crafted appearance. The bars are made by combining the second solid mass phase to a first continuous phase wherein the hardness of the second phase is at least twice the hardness of noodles forming the continuous phase.

Abstract: A cleaning solution for cleaning microelectronic substrates, particularly for post-CMP or via formation cleaning. The cleaning solution comprises a quaternary ammonium hydroxide, an organic amine, a corrosion inhibitor, optionally an organic acid, and water. A preferred cleaning solution comprises tetramethylammonium hydroxide, monoethylanolamine, gallic acid ascorbic acid, and water with the alkalinity of the cleaning solution greater than 0.073 milliequivalents base per gram of solution.

Abstract: According to the present invention there is provided a hard surface cleaning composition for removing cooked-, baked-, or burnt-on food soil from cookware and table ware, having surface tension of less than 30 mN/m and comprising an organic solvent system and no more than: 0.09% by weight of the composition of ethers having molecular weight of less than 210 0.007% by weight of the composition of esters having molecular weight of less than 110 0.045% by weight of the composition of glycol ethers having molecular weight of less than 130 0.0025% by weight of the composition of ketones having molecular weight of less than 90.

Abstract: The invention provides a method for improving the dispensing of a detergent composition or component thereof, comprising a surfactant and other detergent components, by providing a detergent composition comprising an intimate mixture of the surfactant component or part thereof and a crystalline layered silicate.

Abstract: Disclosed are peptides which are peptide derivatives of the HJ loop of a protein tyrosine kinase. The peptides can modulate the activity of the protein tyrosine kinase. Also disclosed are methods of modulating the activity of a protein tyrosine kinase in a subject by administering one of the peptides of the present invention.

Abstract: The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.

Abstract: A leukocyte activating protein factor or a substance originating therein having an effect of inhibiting bone resorption; and novel medicinal utilization thereof. Use of these novel substances with the bone resorption inhibitory effect makes it possible to provide therapeutic methods efficacious against hypercalcemia, osteoporosis, etc.

Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.

Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

Abstract: Method for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequence recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.

Abstract: The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.

Abstract: The present invention is directed to the treatment of cystic fibrosis that involves the administration of a nitrosylating agent, such as S-nitrosoglutathione or ethyl nitrite.

Abstract: A glycosphingolipid having a sugar chain containing &agr;-glucosamine and &bgr;-glucosamine is disclosed. Such glycosphingolipid is advantageous in that possibly being manufactured in a facile and inexpensive manner, and that exhibiting moisturizing effect and immuno-enhancing activity.

Abstract: Tumor cells modified to express one or more T cell costimulatory molecules are disclosed. Preferred costimulatory molecules are B7-2 and B7-3. The tumor cells of the invention can be modified by transfection with nucleic acid encoding B7-2 and/or B7-3, by using an agent which induces or increases expression of B7-2 and/or B7-3 on the tumor cell or by coupling B7-2 and/or B7-3 to the tumor cell. Tumor cells modified to express B7-2 and/or B7-3 can be further modified to express B7. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor.

Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.

Abstract: The invention relates compositions and method for the use of insulin-like growth factor to enhance muscle mass and strength.

Abstract: Described is the use of lithium (Li+) for the preparation of a therapeutic composition for the introduction of a polynucleotide into a cell.

Abstract: New biomaterials essentially constituted by esterified derivatives of hyaluronic acid or by cross-linked derivatives of hyaluronic acid for use in the surgical sector, particularly for use in the prevention of post-surgical adhesion.

Abstract: Compositions and methods for inhibiting arginase activity, including arginase activity in a mammal, are provided. Methods of making the compositions of the invention are also provided as are methods of using the compositions therapeutically. The compositions described herein are useful for alleviating or inhibiting a variety of arinase- and NO synthase-related disorders, including heart disease, gastrointestinal motility disorders, and penile erectile dysfunction in humans.

Abstract: A compound of the structure A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1(vascular cell adhesion molecule-1) and fibronectin; pharmaceutically active compositions comprising these compounds; and the use of these compounds for the control or prevention of diseases states in which &agr;4&bgr;1 is involved are also disclosed.

Abstract: The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.

Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Abstract: A solvent comprising a combination of water and organic solvent(s) capable of dissolving a therapeutically effective amount of medicament(s) not readily soluble in aqueous solvents, said organic solvents including alcohol and glycol, and said medicaments including hydrocortisone.

Abstract: The invention relates to the new 14,15-cyclopropanoandrosteroids of the 19-norandrostane series of the general formula (I) their synthesis and to pharmaceutical compositions containing these compounds. The compounds of formula (I) have an interesting, mixed androgen/gestagen profile, the androgenic or gestagenic activity predominating, depending on the substitution.

Abstract: The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.

Abstract: The present disclosure describes novel compounds of formula (A), wherein R1-R12, X and Y have the meanings given in the specification and compositions containing them which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The compounds described herein are cardiac-sparing.

Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.

Abstract: Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, in

Abstract: A compound of formula wherein R1 is unsubstituted or substituted aryl or heteroaryl, the substituents of the aryl and heteroaryl rings being selected, for example, from the group consisting of OH, halogen, CN, NO2, C1-C6alkyl, C3-C8cycloalkyl, C1-C6alkyl-C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C6alkyl, C1-C6haloalkyl, C3-C8halocycloalkyl, C1-C6alkoxy and phenyl; phenoxy; phenylthio; phenylamino; and phenyl-(C1-C6alkyl)-amino; the substituents of the phenoxy, phenylthio, phenylamino and phenyl-(C1-C6alkyl)-amino groups being selected from the group consisting of halogen, CN, NO2, C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C3-C8halocycloalkyl, C1-C6alkoxy, C3-C8cycloalkoxy, C1-C6alkylthio, C3-C8cycloalkylthio, C1-C6haloalkylthio and C3-C8halocycloalkylthio; R2 is, for example, H, OH, halogen, CN, NO2, C1-C6alkyl or C1-C6alkoxy; A is, for example, a single bond, C1-C12alkylene, O or O(C1-C12alkylene); R4 is H, C1-C6alkyl, C3-C8cycloalkyl, C1-C6haloalkyl, C1-C6alkoxy, N(R5)2 or C1-C6alkoxy-C

Abstract: Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, including stroke. The compounds of this invention have the following structures: wherein n, m, R, R1, R2, X and Ar are as defined herein, including stereoisomes and pharmaceutically acceptable salts thereof.

Abstract: Novel acylhydrazine derivatives exhibiting an inhibitory activity against activated blood coagulation factor X, which are compounds of general formula (I) or salts thereof, wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R1 and R2 are each hydrogen or optionally substituted hydrocarbyl, or alternatively R1 and R2 or the substituent of X1 and R2 may be united to form an optionally substituted ring; X1 and X2 are each free valency, optionally substituted alkylene, or optionally substituted imino; D is oxygen or sulfur; A is —N(R3)—Y— or —N═Y—, R3 is hydrogen, optionally substituted hydrocarbyl, or acyl; Y is an optionally substituted chain hydrocarbon group or an optionally substituted cyclic group; and Z is (1) optionally substituted amino, (2) optionally substituted imidoyl, or (3) an optionally substituted nitrogenous heterocycle group.

Abstract: The invention relates to heterocyclic derivatives, or pharmaceutically-acceptable salts thereof, of formula (I) wherein: A is an optionally substituted 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring heteroatoms selected from oxygen, nitrogen and sulphur atoms; which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to phaautical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.